Annovis’ Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist
Annovis Bio Inc. (NYSE: ANVS) has announced new preclinical data showing a synergistic effect between its lead compound, buntanetap, and the GLP-1 agonist dulaglutide in an Alzheimer's disease mouse model. The combination not only restored cognitive function but also enhanced it beyond healthy control levels. This follows recent data presented at AAIC 2024, where another GLP-1 agonist, liraglutide, showed promise in reducing cognitive decline and brain shrinkage in Alzheimer's patients.
Buntanetap alone restored cognitive function to 100%, while dulaglutide alone achieved 80%. The combination resulted in a 6- to 10-fold increase in efficacy. Annovis CEO Maria Maccecchini highlighted the potential of this approach in developing more effective treatment options for Alzheimer's patients as research shifts towards combination therapies.
Annovis Bio Inc. (NYSE: ANVS) ha annunciato nuovi dati preclinici che mostrano un effetto sinergico tra il suo composto principale, buntanetap, e l'agonista GLP-1 dulaglutide in un modello murino di malattia di Alzheimer. La combinazione non solo ha ripristinato la funzione cognitiva, ma l'ha anche migliorata oltre i livelli di controllo sano. Questo segue dati recenti presentati all'AAIC 2024, dove un altro agonista GLP-1, il liraglutide, ha mostrato promesse nella riduzione del declino cognitivo e della riduzione del volume cerebrale nei pazienti con Alzheimer.
Buntanetap da solo ha ripristinato la funzione cognitiva al 100%, mentre il dulaglutide da solo ha raggiunto l'80%. La combinazione ha portato a un aumento dell'efficacia di 6-10 volte. Il CEO di Annovis, Maria Maccecchini, ha messo in evidenza il potenziale di questo approccio nello sviluppo di opzioni terapeutiche più efficaci per i pazienti con Alzheimer, mentre la ricerca si sposta verso terapie combinate.
Annovis Bio Inc. (NYSE: ANVS) ha anunciado nuevos datos preclínicos que muestran un efecto sinérgico entre su compuesto principal, buntanetap, y el agonista GLP-1 dulaglutide en un modelo de ratón para la enfermedad de Alzheimer. La combinación no solo restauró la función cognitiva, sino que también la mejoró más allá de los niveles sanos de control. Esto sigue a los datos recientes presentados en la AAIC 2024, donde otro agonista GLP-1, el liraglutide, mostró promesas en la reducción del deterioro cognitivo y la reducción del tamaño del cerebro en pacientes con Alzheimer.
Buntanetap por sí solo restauró la función cognitiva al 100%, mientras que el dulaglutide por sí solo alcanzó el 80%. La combinación resultó en un incremento de eficacia de 6 a 10 veces. La CEO de Annovis, Maria Maccecchini, destacó el potencial de este enfoque para desarrollar opciones de tratamiento más efectivas para los pacientes con Alzheimer a medida que la investigación se mueve hacia terapias combinadas.
아노비스 바이오 주식회사 (NYSE: ANVS)는 알츠하이머병 쥐 모델에서 주요 화합물 분타네탭과 GLP-1 작용제 둘라글루타이드시너지를 나타내는 새로운 전임상 데이터를 발표했습니다. 이 조합은 인지 기능을 회복했을 뿐만 아니라 건강한 대조군 수준 이상으로 향상시켰습니다. 이는 AAIC 2024에서 발표된 최근 데이터에 해당하며, 또 다른 GLP-1 작용제인 리라글루타이드가 알츠하이머 환자에서 인지 저하 및 뇌 축소를 줄이는 데 유망한 결과를 보였습니다.
분타네탭 단독으로는 100%의 인지 기능을 회복했으며, 둘라글루타이드 단독으로는 80%에 도달했습니다. 조합 결과 6배에서 10배의 효과 증가가 있었습니다. 아노비스의 CEO인 마리아 마체치니는 이 접근 방식의 잠재력을 강조하며, 연구가 복합 요법으로 전환됨에 따라 알츠하이머 환자에게 더 효과적인 치료 옵션을 개발하고 있다고 언급했습니다.
Annovis Bio Inc. (NYSE: ANVS) a annoncé de nouvelles données précliniques montrant un effet synergique entre son composé phare, buntanetap, et l'agoniste GLP-1 dulaglutide dans un modèle murin de la maladie d'Alzheimer. La combinaison a non seulement restauré la fonction cognitive, mais a également dépassé les niveaux de contrôle sains. Cela fait suite à des données récentes présentées lors de l'AAIC 2024, où un autre agoniste GLP-1, le liraglutide, a montré des promesses pour réduire le déclin cognitif et la rétrécissement du cerveau chez les patients atteints d'Alzheimer.
Buntanetap à lui seul a restauré la fonction cognitive à 100%, tandis que dulaglutide à lui seul a atteint 80%. La combinaison a entraîné une augmentation de l'efficacité de 6 à 10 fois. La PDG d'Annovis, Maria Maccecchini, a souligné le potentiel de cette approche pour développer des options de traitement plus efficaces pour les patients atteints d'Alzheimer alors que la recherche se tourne vers des thérapies combinées.
Annovis Bio Inc. (NYSE: ANVS) hat neue präklinische Daten veröffentlicht, die einen synergistischen Effekt zwischen seinem Hauptbestandteil, buntanetap, und dem GLP-1-Agonisten dulaglutide in einem Alzheimer-Mausmodell zeigen. Die Kombination hat nicht nur die kognitive Funktion wiederhergestellt, sondern auch über die gesunden Kontrollwerte hinaus verbessert. Dies folgt auf aktuelle Daten, die auf der AAIC 2024 präsentiert wurden, wo ein anderer GLP-1-Agonist, Liraglutid, vielversprechende Ergebnisse bei der Verringerung des kognitiven Abbaus und der Schrumpfung des Gehirns bei Alzheimer-Patienten zeigte.
Buntanetap allein stellte die kognitive Funktion auf 100% wieder her, während Dulaglutid allein 80% erreichte. Die Kombination führte zu einem 6- bis 10-fachen Anstieg der Wirksamkeit. Die CEO von Annovis, Maria Maccecchini, hob das Potenzial dieses Ansatzes hervor, um effektivere Behandlungsoptionen für Alzheimer-Patienten zu entwickeln, da sich die Forschung zunehmend auf Kombinationstherapien konzentriert.
- Buntanetap combined with dulaglutide showed synergistic effect in Alzheimer's mouse model
- Combination therapy enhanced cognitive function beyond healthy control levels
- Buntanetap alone restored cognitive function to 100% in animal model
- 6- to 10-fold increase in efficacy observed with combination therapy
- None.
Insights
The synergistic effect of buntanetap and dulaglutide in an Alzheimer's mouse model is a significant breakthrough. This combination not only restored cognitive function but enhanced it beyond healthy control levels, which is extraordinary. The
The choice of dulaglutide for its superior BBB permeability demonstrates thoughtful experimental design. This approach could lead to more effective treatments with lower doses, potentially reducing side effects. However, it's important to note that mouse model results don't always translate directly to human outcomes. The next critical step will be human trials to confirm these promising results.
This preclinical data positions Annovis Bio favorably in the competitive Alzheimer's drug market. The synergistic effect with GLP-1 agonists, already approved for other conditions, could accelerate the path to market through combination therapy trials. This approach aligns with the industry trend towards multi-target treatments for complex neurological disorders.
Investors should note that while promising, preclinical results are early-stage. The company's ability to replicate these results in human trials will be crucial. Additionally, the potential for partnering with GLP-1 agonist manufacturers could open new revenue streams and development opportunities. However, the road to FDA approval remains long and costly, with many potential hurdles ahead.
The combination of buntanetap and dulaglutide showing cognitive enhancement beyond normal levels is intriguing but requires cautious interpretation. While restoring function to 100% is the primary goal in Alzheimer's treatment, the implications of cognitive enhancement beyond normal levels are unclear and may raise safety concerns.
The synergistic effect could allow for lower doses of each drug, potentially reducing side effects - a important factor in Alzheimer's treatment where patient compliance is challenging. However, long-term effects of such cognitive enhancement need thorough investigation. As we move towards combination therapies in Alzheimer's treatment, this approach shows promise, but rigorous clinical trials focusing on both efficacy and safety are essential before drawing definitive conclusions.
MALVERN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced new preclinical data demonstrating the synergistic effect of its lead compound, buntanetap, when combined with the glucagon-like peptide 1 (GLP-1) agonist dulaglutide (Trulicity®) in a mouse model of Alzheimer’s disease.
GLP-1 agonists, commonly used to treat diabetes, weight loss, and heart conditions, are now showing promising potential in the treatment of Alzheimer’s disease. Recent data presented at the Alzheimer’s Association International Conference® (AAIC®) 2024 revealed that another GLP-1 agonist, liraglutide (Victoza), was able to decrease cognitive decline in Alzheimer’s patients by
In 2018, Annovis Bio published data showing that buntanetap fully restored memory, learning, and synaptic potentiation in an Alzheimer’s mouse model (Teich et al. 2018). Building on this research, Annovis recently investigated whether combining buntanetap with the GLP-1 agonist dulaglutide would produce a synergistic effect in the same animal model. The results were compelling: while buntanetap alone restored cognitive function to
The ability of GLP-1 agonists to penetrate the brain is linked to their molecular structure. Single-chain peptides (i.e. dulaglutide, albiglutide, exenatide) have better blood-brain barrier (BBB) permeability than bifurcated molecules containing side chains. Due to its excellent BBB permeability, dulaglutide was chosen from other GLP-1 agonists for combination with buntanetap (Figure 2).
“We are excited to see that buntanetap significantly amplifies the effects of dulaglutide on memory and learning, with a 6- to 10-fold increase in efficacy,” said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio. “This synergy is particularly important for enhancing treatment outcomes while minimizing potential side effects. As the field of Alzheimer’s research shifts towards combination therapies, we believe our approach holds great promise for offering more effective treatment options for patients.”
About Buntanetap
Buntanetap (formerly known as Posiphen) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This improves synaptic transmission, axonal transport, and reduces neuroinflammation. Dysregulation of these pathways has been shown to cause nerve cell degeneration and ultimately nerve cell death. By targeting these pathways, buntanetap has the potential to reverse neurodegeneration in Alzheimer’s, Parkinson’s, and other neurodegenerative diseases, thereby aiming to restore brain function and improve the quality of life for patients.
About Annovis Bio, Inc.
Headquartered in Malvern, Pennsylvania, Annovis Bio Inc. is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for Email Alerts at https://www.Annovisbio.com/email-alerts.
Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, the Company's plans related to clinical trials. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such risks and uncertainties include, but are not limited to, those related to patient enrollment, the effectiveness of Buntanetap, and the timing, effectiveness, and anticipated results of the Company's clinical trials evaluating the efficacy, safety, and tolerability of Buntanetap. Additional risk factors are detailed in the Company's periodic filings with the SEC, including those listed in the "Risk Factors" section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements in this press release are based on information available to the Company as of the date of this release. The Company expressly disclaims any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contacts
Annovis Bio, Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com
Investor Contact
Scott McGowan
InvestorBrandNetwork (IBN)
Phone: 310.299.1717
IR@annovisbio.com
Investor Website
Attachments
FAQ
What is the synergistic effect of buntanetap and dulaglutide in Alzheimer's treatment?
How effective was buntanetap alone in restoring cognitive function in the Alzheimer's mouse model?
What recent data was presented at AAIC 2024 regarding GLP-1 agonists and Alzheimer's disease?
Why did Annovis Bio choose dulaglutide for combination with buntanetap in their Alzheimer's research?
